SNDL Seeks Shareholder Approval for 1:2–1:10 Reverse Split to Regain Nasdaq Compliance
SNDL sits 24% above its 52-week low of $1.165.
Summary
SNDL is seeking shareholder approval for a reverse stock split between 1:2 and 1:10 to maintain Nasdaq listing compliance, alongside a board reduction from seven to five directors.
Key Events · Corporate Governance and Compliance · SNDL
-
Reverse Split Proposed
Shareholders will vote October 15, 2026 on a share consolidation at a ratio between 1:2 and 1:10, with the board targeting implementation before October 31, 2026.
-
Nasdaq Compliance Driver
The board states the split is intended to lift the share price above the US$1.00 Nasdaq minimum bid requirement and broaden institutional investor eligibility.
-
Board Reduced to Five
J. Carlo Cannell and Frank Krasovec are not standing for re-election, cutting the board from seven to five members.
-
Auditor Confirmation
CBIZ CPAs P.C. (successor to Marcum LLP) is proposed for re-appointment as auditor.
Analysis · SNDL · Life Sciences
SNDL is asking shareholders to approve a reverse stock split at a ratio between 1:2 and 1:10, with the board targeting implementation before October 31, 2026. The company states the move is designed to lift the share price above the US$1.00 Nasdaq minimum bid threshold and attract institutional investors that screen out low-priced stocks. With 246.1 million shares outstanding and the stock trading at $1.44, the split would mechanically reduce the share count and raise the per-share price, but it does not change the company's market value or fix the underlying business challenges — SNDL reported a C$7.8 million Q2 loss in July. The filing also reduces the board from seven to five directors, dropping two long-serving members, and confirms CBIZ CPAs as auditor. The vote is set for October 15, 2026.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNDL was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $357.6M. The 52-week trading range was $1.17 to $2.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.